We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.3B
$68.4M 1.37%
519,279
+103,379
+25% +$11.9M
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.62B
$67.3M 1.34%
697,500
+168,300
+32% +$16.1M
ELV icon
28
Elevance Health
ELV
$82.7B
$66.7M 1.33%
+141,500
New +$65.4M
THRD
29
DELISTED
Third Harmonic Bio
THRD
$63.4M 1.27%
5,779,071
– –
NTRA icon
30
Natera
NTRA
$36.4B
$59.8M 1.19%
954,481
+33,900
+4% +$1.69M
CRNX icon
31
Crinetics Pharmaceuticals
CRNX
$8.88B
$59.3M 1.18%
1,667,360
-1,228,714
-42% -$37.7M
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
$55.2M 1.1%
922,200
-338,300
-27% -$17.2M
RCM
33
DELISTED
R1 RCM Inc. Common Stock
RCM
$50.8M 1.01%
4,803,200
+1,362,200
+40% +$15.4M
SPRY icon
34
ARS Pharmaceuticals
SPRY
$563M
$50.6M 1.01%
9,240,887
– –
KROS icon
35
Keros Therapeutics
KROS
$198M
$50.4M 1.01%
1,268,734
-246,000
-16% -$7.71M
HUM icon
36
Humana
HUM
$43.8B
$50.3M 1%
109,900
-232,600
-68% -$115M
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$49.4M 0.99%
7,619,135
– –
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
$48.3M 0.97%
2,535,245
-1,546,347
-38% -$21.5M
SIBN icon
39
SI-BONE Inc
SIBN
$804M
$48.1M 0.96%
2,292,531
– –
PRLD icon
40
Prelude Therapeutics
PRLD
$362M
$46.6M 0.93%
10,909,256
– –
ALXO icon
41
ALX Oncology
ALXO
$262M
$46.1M 0.92%
3,095,000
+224,000
+8% +$2.13M
NPCE icon
42
Neuropace
NPCE
$490M
$41.3M 0.82%
4,003,967
-8,314
-0.2% -$66.3K
IOVA icon
43
Iovance Biotherapeutics
IOVA
$2.04B
$38.3M 0.76%
4,707,458
– –
SNDX icon
44
Syndax Pharmaceuticals
SNDX
$1.68B
$37.8M 0.75%
1,749,000
+465,000
+36% +$7.15M
ICLR icon
45
Icon
ICLR
$13.7B
$37.4M 0.75%
132,200
– –
UNH icon
46
UnitedHealth
UNH
$387B
$36.9M 0.74%
70,000
– –
AMGN icon
47
Amgen
AMGN
$212B
$36.7M 0.73%
127,300
– –
APGE icon
48
Apogee Therapeutics
APGE
$10.1B
$35.7M 0.71%
1,277,901
-150,000
-11% -$3.01M
JANX icon
49
Janux Therapeutics
JANX
$901M
$35.6M 0.71%
3,317,927
– –
CMPX icon
50
Compass Therapeutics
CMPX
$358M
$34.9M 0.7%
22,362,850
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.